Diogo Martins Branco: Editorial on real world data to support policy and clinical decision-making
Diogo Martins Branco, Medical Oncologist at ESMO, shared a post on X:
“Insightful editorial on ESMO Daily Reporter by our ESMO Director of Policy, Jean-Yves Blay.
The results of our survey presented today at ESMO Rare Cancers 2025 illustrate the increasing acceptance of high-quality Real World Data to support policy and clinical decision-making. – Diogo Martins Branco
Healthcare professionals (HCP) and regulators share a positive perception of the use of high-quality RWD as an external comparator to single-arm trials of advanced cancer of high unmet medical need.
Higher trust in overall survival benefit was associated with higher acceptability of severe toxicity increase – patient advocates are needed in the discussion to define standard safety data that needs to be reported in EHRs so that RWD can generate proper safety RWE.
Differences between HCP and regulators on familiarity with RWD studies and beliefs related to advantages/disadvantages of RWD studies – call for activities that increase alignment.
Quality attributes in RWD studies must be clearly defined for the streamlined use of this methodology – ESMO RWDD Taskforce is committed to expanding RWE quality standards beyond the pioneer ESMO Grow RWE reporting guidance.”
Dario Trapani, Medical Oncologist at the European Institute of Oncology, shared this post on X, adding:
“Don’t miss Diogo Martins Branco et Al’s work on RWE to design the contourns of regulatory trade-off of acceptability of evidence from single arm trials!”
More posts featuring Real World Data on OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023